Literature DB >> 23638233

Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.

Qihua Gu1, Chengping Hu, Jingjing Qu.   

Abstract

UNLABELLED: Malignant pleural effusion in patients with cancers or malignant pleural mesothelioma may often appear at the late stage of disease and significantly affect the patients' life quality and survival. However, there is still no very effective treatment to control malignant pleural effusion. Here we report that malignant pleural effusion in one patient was completely relieved for 15 months by the anti-tuberculosis therapy. CASE
PRESENTATION: A 54-year-old female patient complained of cough, dyspnea, chest pain, night sweat and light fever in the afternoon. Computed tomography (CT) of the chest revealed bilateral pleural effusion. But no tumor was found in the lung, pleura and in other sites. Blood test revealed serum carcinoembryonic antigen (CEA) level at 300 ng/mL. One week after we tried anti-tuberculosis combined therapy with isoniazid, pyrazinamide, rifapentine and ethambutol. The pleural effusion in patient was eliminated, along with decreasing CEA. But the CEA increased gradually again when the anti-tuberculosis treatment was forced to discontinuation. Sixteen months after anti-tuberculosis treatment, the symptoms of cough and breathing difficulty relapsed. Chest CT revealed left pleural effusion, pleural thickness and pericardium nodules. Thoracoscopy and biopsy were conducted. The pleural nodules specimen was pathologically diagnosed as squamous cell carcinoma.
CONCLUSION: We reported a rare case of successfully treating malignant pleural effusion caused by squamous cell carcinoma of unknown primary site with the anti-tuberculosis combined. This report provides useful evidences for that the anti-tubercular agents may have potential anticancer activity in some carcinomas.

Entities:  

Keywords:  Malignant pleural effusion; anti-tuberculosis therapy; carcinoembryonic antigen (CEA)

Mesh:

Substances:

Year:  2013        PMID: 23638233      PMCID: PMC3638112     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  11 in total

1.  Synthesis, mutagenicity, binding to pBR 322 DNA and antitumour activity of platinum(II) complexes with ethambutol.

Authors:  M Coluccia; F P Fanizzi; G Giannini; D Giordano; F P Intini; G Lacidogna; F Loseto; M A Mariggio; A Nassi; G Natile
Journal:  Anticancer Res       Date:  1991 Jan-Feb       Impact factor: 2.480

Review 2.  Pleural effusions.

Authors:  Richard W Light
Journal:  Med Clin North Am       Date:  2011-09-25       Impact factor: 5.456

3.  A clinicopathological study of resected small-sized squamous cell carcinomas of the peripheral lung: prognostic significance of serum carcinoembryonic antigen levels.

Authors:  Takuya Nagashima; Yukinori Sakao; Mingyon Mun; Yuichi Ishikawa; Ken Nakagawa; Munetaka Masuda; Sakae Okumura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2012-12-13       Impact factor: 1.520

4.  Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications.

Authors:  Lama Sakr; Fabien Maldonado; Laurent Greillier; Hervé Dutau; Anderson Loundou; Philippe Astoul
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

5.  Carcinoembryonic antigen level in serum and pleural lavage fluid in non-small cell lung cancer.

Authors:  M Tomita; T Shimizu; T Ayabe; A Yonei; T Onitsuka
Journal:  Thorac Cardiovasc Surg       Date:  2010-09-07       Impact factor: 1.827

6.  Pyrazinamide potential effects on male rats DNA fragmentation, bone type I collagen amino acid composition, reproductive capability and posterity antenatal and postnatal development.

Authors:  Larysa B Bondarenko; Ganna M Shayakhmetova; Taisiya F Byshovets; Valentina M Kovalenko
Journal:  Acta Pol Pharm       Date:  2012 Sep-Oct       Impact factor: 0.330

7.  Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.

Authors:  Stefano M M Basso; Francesco Mazza; Bernardo Marzano; Davide A Santeufemia; Giordano B Chiara; Franco Lumachi
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

Review 8.  Causes and management of common benign pleural effusions.

Authors:  Rajesh Thomas; Y C Gary Lee
Journal:  Thorac Surg Clin       Date:  2013-02       Impact factor: 1.750

Review 9.  Pleural effusion in lung cancer: more questions than answers.

Authors:  Marios E Froudarakis
Journal:  Respiration       Date:  2012-05-07       Impact factor: 3.580

Review 10.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more
  2 in total

Review 1.  Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.

Authors:  Panwen Tian; Yongchun Shen; Chun Wan; Ting Yang; Jing An; Qun Yi; Lei Chen; Tao Wang; Ye Wang; Fuqiang Wen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  The Intrapleural Bridge Connection is One of the Reasons for Unknown Localized Pleural Adhesion.

Authors:  Qihua Gu; Xinhao Deng; Zhao Li; Jing Wang; Chengping Hu; Shuhua Lei; Xiaoling Cai
Journal:  Int J Gen Med       Date:  2021-04-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.